X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Metoject subcutaneous injection pen (methotrexate) works by inhibiting dihydrofolic acid reductase enzyme. It is approved for the treatment of rheumatoid arthritis.
Lead Product(s): Methotrexate
Therapeutic Area: Immunology Product Name: Metoject
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Under the agreement, UroGen will develop a next-generation novel mitomycin-based formulation, UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, for urothelial cancers.
Lead Product(s): Mitomycin
Therapeutic Area: Oncology Product Name: UGN-103
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: UroGen Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 17, 2024
Details:
Primary endpoint of ACR20 response* at 12 weeks was 59.6% in Metoject (Methotrexate) group versus 51.0% in oral MTX group, indicating comparable efficacy. Adverse drug reaction incidence rates in this trial were 25.0% in the Metoject group and 34.0% in the oral MTX group.
Lead Product(s): Methotrexate
Therapeutic Area: Immunology Product Name: Metoject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
Under the terms of the agreement, medac receives an exclusive license to commercialize oNKord® (GTA002) in the EU, the UK and further European countries for acute myeloid leukemia (AML) and multiple myeloma (MM) patients.
Lead Product(s): GTA002,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: oNKord
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Glycostem Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 01, 2022
Details:
Antibody part of SYD985 (trastuzumab duocarmazine) binds to HER2 on surface of cancer cell and the ADC is internalized by cell. After proteolytic cleavage of linker, the inactive cytotoxin is activated and DNA damage is induced, resulting in tumor cell death.
Lead Product(s): (vic-) Trastuzumab Duocarmazine
Therapeutic Area: Oncology Product Name: SYD985
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Byondis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
Study found event-free survival and overall survival superior after Trecondyv (treosulfan) compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm.
Lead Product(s): Treosulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Trecondyv
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Medexus Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Treosulfan will be marketed in Canada under the brand name Trecondyv® and indicated in combination with fludarabine as part of a conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (“allo-HSCT”).
Lead Product(s): Treosulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Trecondyv
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medexus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 12, 2021
Details:
Medac intends to leverage its strong, existing commercial infrastructure in the United States to address the underserved allo-HSCT market through its commercialization of treosulfan.
Lead Product(s): Treosulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Trecondi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medexus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 02, 2021
Details:
Medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fresenius Kabi AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
